Cargando…
2812. Clinical Impact of the Ceftolozane-Tazobactam Shortage on Difficult-To-Treat Resistant Pseudomonas aeruginosa Infections at an Academic Medical Center
BACKGROUND: Difficult-to-treat resistant Pseudomonas aeruginosa (DTR PA) infections are a serious threat, requiring treatment with ceftolozane-tazobactam (C/T), ceftazidime-avibactam, or imipenem-cilastatin-relebactam due to extensive resistance. C/T was unavailable January to December 2021 so alter...
Autores principales: | Vance, Mary K, Cimino, Christo, Ereshefsky, Benjamin, Humphries, Romney, Nelson, George E |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678476/ http://dx.doi.org/10.1093/ofid/ofad500.2423 |
Ejemplares similares
-
Deciphering the Evolution of Cephalosporin Resistance to Ceftolozane-Tazobactam in Pseudomonas aeruginosa
por: Barnes, Melissa D., et al.
Publicado: (2018) -
Ceftolozane/Tazobactam Dosing Requirements Against Pseudomonas aeruginosa Bacteremia
por: Ruiz, Jesus, et al.
Publicado: (2020) -
Ceftolozane/Tazobactam Resistance and Mechanisms in Carbapenem-Nonsusceptible Pseudomonas aeruginosa
por: Teo, Jocelyn Qi-Min, et al.
Publicado: (2021) -
Ceftolozane–tazobactam- and ceftazidime–avibactam-resistant Pseudomonas aeruginosa mastoiditis
por: Jacobs, Jeremy, et al.
Publicado: (2020) -
Reproducibility of Ceftolozane/Tazobactam MIC Results for Enterobacteriaceae and Pseudomonas aeruginosa Using MicroScan Dried Gram-negative MIC Panels
por: Harrington, Amanda, et al.
Publicado: (2017)